Brought to you by 
Apple Tree leads $50mm Series B round for Syntimmune
21 Jun 2017
Executive Summary
Syntimmune Inc. (developing immune disease therapies targeting the neonatal Fc receptor (FcRn)) raised $50mm through its Series B round. Apple Tree Partners led with a $48mm investment, and was joined by other existing backers. The funds will support development activities including two ongoing Phase Ib/IIa studies with lead monoclonal antibody candidate SYNT001 for pemphigus and warm autoimmune hemolytic anemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Apple Tree leads $50mm Series B round for Syntimmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice